Bausch+Lomb Results Presentation Deck
Expansion of Surgical Portfolio
Strategic Agreements Designed to Address Unmet Needs in Glaucoma
Entered into an exclusive European distribution agreement for MIMS® minimally invasive surgical
procedure, as well as option agreement to acquire the assets of Sanoculis
Exclusive European distribution agreement for
Sanoculis' Minimally Invasive Micro Sclerostomy
("MIMSⓇ"), an innovative minimally invasive surgical
procedure for the treatment of glaucoma
MIMS® is a stentless, simple and fast glaucoma
treatment that effectively lowers intraocular pressure
without the need for invasive surgery.
Bausch+Lomb made an equity investment in Sanoculis as
part of a Series C round of funding and has an option to
acquire all of the assets of Sanoculis
I
BAUSCH + LOMB 1. World Glaucoma Association. Retrieved from Glaucoma Information Statistics - Glaucoma Information (glaucomapatients.org).
AUALS &
Current Market
79.6M
individuals globally
had glaucoma in 20201
+40%
increase in individuals
globally expected to have
glaucoma by 2040 (or
111.8M individuals)¹
19View entire presentation